A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer
Primary Purpose
Esophageal Carcinoma in Situ AJCC V7
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
PDT
ESD
Sponsored by
About this trial
This is an interventional treatment trial for Esophageal Carcinoma in Situ AJCC V7 focused on measuring Early esophageal carcinoma, Photodynamics Therapy, Endoscopic submucosal dissection
Eligibility Criteria
Inclusion Criteria:
- High-grade intraepithelial neoplasia of the esophagus
- 18-80 years old
- The tumor was confined to the lamina propria of the mucosa
- The tumor invaded the submucosa and was limited to 200 microns
Exclusion Criteria:
- The tumor invaded the entire circumference of the esophagus
- The tumor invaded the muscularis or submucosa more than 200 microns
- The patient has difficulty tolerating anesthesia due to other diseases
- Pregnant or breastfeeding women
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
PDT group
ESD group
Arm Description
After enrollment, patients were injected with photosensitizer at a dose of 2mg/kg, and received photodynamic irradiation 48 hours later.
Patients received standard ESD treatment after enrollment
Outcomes
Primary Outcome Measures
2-year disease-free survival rate
The percent of 2 year disease-free survival after random allocation, percent
Secondary Outcome Measures
Esophageal stenosis rate at 3 months
Stenosis rate of esophagus after 3 months
Full Information
NCT ID
NCT05208775
First Posted
January 10, 2022
Last Updated
January 17, 2022
Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
1. Study Identification
Unique Protocol Identification Number
NCT05208775
Brief Title
A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer
Official Title
A Phase III, Randomized, Controlled Study of Endoscopic Submucosal Dissection Versus Photodynamic Therapy for Early Esophageal Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 1, 2022 (Anticipated)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
December 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The purpose of this study was to compare the efficacy and safety of Photodynamic therapy (PDT) and Endoscopic submucosal (ESD) dissection in the treatment of early esophageal cancer.
Detailed Description
Background: Photodynamic therapy (PDT) is recommended by the NCCN guidelines as an effective method for the treatment of early esophageal cancer. However, there is no clinical trial data so far on whether its efficacy can be compared with that of standard Endoscopic submucosal (ESD). Our team will conduct a detailed study on it.
Aim: to compare the efficacy and safety of Photodynamic therapy (PDT) and Endoscopic submucosal (ESD) dissection in the treatment of early esophageal cancer.
Methods: This study intends to recruit 46 patients with early esophageal cancer and randomly divide them into two groups: one group to receive ESD and the other group to receive PDT.The efficacy and safety were observed after 2 years of follow-up.
Primary endpoints: The recurrence rates at 3 months, 6 months, and 2 years were compared.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Carcinoma in Situ AJCC V7
Keywords
Early esophageal carcinoma, Photodynamics Therapy, Endoscopic submucosal dissection
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
46 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PDT group
Arm Type
Experimental
Arm Description
After enrollment, patients were injected with photosensitizer at a dose of 2mg/kg, and received photodynamic irradiation 48 hours later.
Arm Title
ESD group
Arm Type
Active Comparator
Arm Description
Patients received standard ESD treatment after enrollment
Intervention Type
Procedure
Intervention Name(s)
PDT
Other Intervention Name(s)
Photodynamics Therapy
Intervention Description
Drug: (Hematoporphyrin sodium injection) Hematoporphyrin sodium injection (xibofen):2mg/kg I.V.
Laser irradiation:
48 hours after the patient input the photosensitizer, the laser irradiation time is 900 seconds, and the output power is 200 watts.
Intervention Type
Procedure
Intervention Name(s)
ESD
Other Intervention Name(s)
Endoscopic submucosal dissection
Intervention Description
The patients received standard endoscopic submucosal dissection after enrollment.
Primary Outcome Measure Information:
Title
2-year disease-free survival rate
Description
The percent of 2 year disease-free survival after random allocation, percent
Time Frame
2 year
Secondary Outcome Measure Information:
Title
Esophageal stenosis rate at 3 months
Description
Stenosis rate of esophagus after 3 months
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
High-grade intraepithelial neoplasia of the esophagus
18-80 years old
The tumor was confined to the lamina propria of the mucosa
The tumor invaded the submucosa and was limited to 200 microns
Exclusion Criteria:
The tumor invaded the entire circumference of the esophagus
The tumor invaded the muscularis or submucosa more than 200 microns
The patient has difficulty tolerating anesthesia due to other diseases
Pregnant or breastfeeding women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shegan Gao, MD, PhD
Phone
18638859977
Email
gsg112258@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Tanyou Shan, MD, PhD
Phone
18537976669
Email
shantanyoudoctor@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shegan Gao, MD, PhD
Organizational Affiliation
The First Affiliated Hospital and College of Henan University of Science and Technology
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Tanyou Shan, MD, PhD
Organizational Affiliation
The First Affiliated Hospital and College of Henan University of Science and Technology
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Lijuan Wu, MD, PhD
Organizational Affiliation
The First Affiliated Hospital and College of Henan University of Science and Technology
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Caihong Dong, MD,PhD
Organizational Affiliation
The First Affiliated Hospital and College of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jiachun Sun, MD, PhD
Organizational Affiliation
The First Affiliated Hospital and College of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wanying Li, MD
Organizational Affiliation
The First Affiliated Hospital and College of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xiaozhi Yuan, MD, PhD
Organizational Affiliation
The First Affiliated Hospital and College of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mengxi Zhang, MD
Organizational Affiliation
The First Affiliated Hospital and College of Henan University of Science and Technology
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34202917
Citation
Yano T, Minamide T, Takashima K, Nakajo K, Kadota T, Yoda Y. Clinical Practice of Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer. J Clin Med. 2021 Jun 24;10(13):2785. doi: 10.3390/jcm10132785.
Results Reference
background
PubMed Identifier
31156297
Citation
National Health Commission Of The People's Republic Of China. Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version). Chin J Cancer Res. 2019 Apr;31(2):223-258. doi: 10.21147/j.issn.1000-9604.2019.02.01. No abstract available.
Results Reference
background
PubMed Identifier
32578508
Citation
Zeng R, Liu C, Li L, Cai X, Chen R, Li Z. Clinical Efficacy of HiPorfin Photodynamic Therapy for Advanced Obstructive Esophageal Cancer. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820930335. doi: 10.1177/1533033820930335.
Results Reference
background
PubMed Identifier
23019392
Citation
Yoon HY, Cheon YK, Choi HJ, Shim CS. Role of photodynamic therapy in the palliation of obstructing esophageal cancer. Korean J Intern Med. 2012 Sep;27(3):278-84. doi: 10.3904/kjim.2012.27.3.278. Epub 2012 Sep 1.
Results Reference
background
PubMed Identifier
28983230
Citation
Itabashi M, Nasierowska-Guttmejer A, Shimoda T, Majewski P, Rezner W, Sikora K, Srutek E, Steplewska K, Swatek J, Szumilo J, Wierzchniewska-Lawska A, Wronecki L, Zembala-Nozynska E, Arai T, Fujita M, Kawachi H, Unakami M, Kamoshida T. The importance of the concept and histological criteria of "intraepithelial squamous cell carcinoma" of the esophagus: in comparison between Western and Japanese criteria. Esophagus. 2017;14(4):333-342. doi: 10.1007/s10388-017-0583-7. Epub 2017 Jun 14.
Results Reference
background
PubMed Identifier
30588952
Citation
Zheng JY, Chen YH, Chen YY, Zheng XL, Zhong SS, Deng WY, Zheng JH, Guo XB, Gao LY, Liang W. Presence of pink-color sign within 1 min after iodine staining has high diagnostic accordance rate for esophageal high-grade intraepithelial neoplasia/invasive cancer. Saudi J Gastroenterol. 2019 Mar-Apr;25(2):113-118. doi: 10.4103/sjg.SJG_274_18.
Results Reference
background
PubMed Identifier
33937514
Citation
Omae M, Hagstrom H, Ndegwa N, Vieth M, Wang N, Vujasinovic M, Baldaque-Silva F. Wide-field endoscopic submucosal dissection for the treatment of Barrett's esophagus neoplasia. Endosc Int Open. 2021 May;9(5):E727-E734. doi: 10.1055/a-1386-3668. Epub 2021 Apr 22.
Results Reference
background
PubMed Identifier
19152456
Citation
Wu W, Wu YL, Zhu YB, Wei Q, Guo Y, Zhu ZG, Yuan YZ. Endoscopic features predictive of gastric cancer in superficial lesions with biopsy-proven high grade intraepithelial neoplasia. World J Gastroenterol. 2009 Jan 28;15(4):489-95. doi: 10.3748/wjg.15.489.
Results Reference
background
PubMed Identifier
30922862
Citation
Ke Y, van Munster SN, Xue L, He S, Zhang Y, Dou L, Liu Y, Liu X, Liu Y, Li W, Lv N, Dawsey SM, Weusten BLAM, Bergman JJGHM, Wang G. Prospective study of endoscopic focal cryoballoon ablation for esophageal squamous cell neoplasia in China. Gastrointest Endosc. 2019 Aug;90(2):204-212. doi: 10.1016/j.gie.2019.03.017. Epub 2019 Mar 25.
Results Reference
background
Learn more about this trial
A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer
We'll reach out to this number within 24 hrs